Maxime Lehmann

ORCID

Publication Activity (10 Years)

Years Active: 2019-2022
Publications (10 Years): 5

Top Venues

Cancers

Cellular and molecular life sciences : CMLS

Pharmaceutics

Cells

This page only lists publications with an associated author ORCID identifier.

Publications

Elisabete Cruz Da Silva, Sophie Foppolo, Benoît Lhermitte, Marina Ingremeau, Hélène Justiniano, Lorraine Klein, Marie-Pierre Chenard, Romain Vauchelles, Basma Abdallah, Maxime Lehmann, Nelly Etienne-Selloum, Monique Dontenwill, Laurence Choulier
Bioimaging Nucleic-Acid Aptamers with Different Specificities in Human Glioblastoma Tissues Highlights Tumoral Heterogeneity. Pharmaceutics 14 (10) (2022)
Antoine Mousson, Marlène Legrand, Tania Steffan, Romain Vauchelles, Philippe Carl, Jean-Pierre Gies, Maxime Lehmann, Guy Zuber, Jan De Mey, Denis Dujardin, Emilie Sick, Philippe Rondé
Inhibiting FAK-Paxillin Interaction Reduces Migration and Invadopodia-Mediated Matrix Degradation in Metastatic Melanoma Cells. Cancers 13 (8) (2021)
Elisabete Cruz Da Silva, Laurence Choulier, Jessica Thevenard-Devy, Christophe Schneider, Philippe Carl, Philippe Rondé, Stéphane Dedieu, Maxime Lehmann
Role of Endocytosis Proteins in Gefitinib-Mediated EGFR Internalisation in Glioma Cells. Cells 10 (11) (2021)
Anne-Florence Blandin, Elisabete Cruz Da Silva, Marie-Cécile Mercier, Oleksandr Glushonkov, Pascal Didier, Stéphane Dedieu, Cristophe Schneider, Jessica Devy, Nelly Etienne-Selloum, Monique Dontenwill, Laurence Choulier, Maxime Lehmann
Gefitinib induces EGFR and α5β1 integrin co-endocytosis in glioblastoma cells. Cellular and molecular life sciences : CMLS 78 (6) (2020)
Elisabete Cruz da Silva, Monique Dontenwill, Laurence Choulier, Maxime Lehmann
Role of Integrins in Resistance to Therapies Targeting Growth Factor Receptors in Cancer. Cancers 11 (5) (2019)

Maxime Lehmann.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Maxime Lehmann